PE20110773A1 - Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, y su preparacion - Google Patents

Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, y su preparacion

Info

Publication number
PE20110773A1
PE20110773A1 PE2011001127A PE2011001127A PE20110773A1 PE 20110773 A1 PE20110773 A1 PE 20110773A1 PE 2011001127 A PE2011001127 A PE 2011001127A PE 2011001127 A PE2011001127 A PE 2011001127A PE 20110773 A1 PE20110773 A1 PE 20110773A1
Authority
PE
Peru
Prior art keywords
piperidinone
decan
ona
aza
oxa
Prior art date
Application number
PE2011001127A
Other languages
English (en)
Inventor
Zhongli Gao
Ryan Hartung
David Stefany
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20110773A1 publication Critical patent/PE20110773A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE TETRAHIDROPIRAN ESPIRO PIRROLIDINONA Y PIPERIDINONA SUSTITUIDOS DE FORMULA (I) DONDE R1 ES H, ALQUILO(C1-C4), CF3 O ALCOXI(C1-C4)-ALQUILO(C1-C4); R2 ES H, HALOGENO, ALQUILO(C1-C4) O CF3; m, n Y p SON CADA UNO 1 O 2. SON COMPUESTOS PREFERIDOS: 2-[4-((2S,3'S)-2-METIL-[1,3']BIPIRROLIDINIL-1'-IL)-FENIL]-8-OXA-2-AZA-ESPIRO[4.5]DECAN-1-ONA; 2-{2-METIL-4-[4-((S)-2-METIL-PIRROLIDIN-1-IL)-PIPERIDIN-1-IL]-FENIL}-8-OXA-2-AZA-ESPIRO[4.5]DECAN-1-ONA; 2-[2-FLUORO-4-(2-ISOPROPIL-[1,3']BIPIRROLIDINIL-1'-IL)-FENIL]-8-OXA-2-AZA-ESPIRO[4.5]DECAN-1-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES DE HISTAMINA H3 SIENDO UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA, ENFERMEDAD DE ALZHEIMER, ENFERMEDAD DE PARKINSON, EPILEPSIA, INSOMNIO
PE2011001127A 2008-12-05 2009-12-04 Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, y su preparacion PE20110773A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12008708P 2008-12-05 2008-12-05
FR0955909 2009-08-28

Publications (1)

Publication Number Publication Date
PE20110773A1 true PE20110773A1 (es) 2011-10-26

Family

ID=41665099

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001127A PE20110773A1 (es) 2008-12-05 2009-12-04 Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, y su preparacion

Country Status (27)

Country Link
US (2) US8217052B2 (es)
EP (1) EP2373659B1 (es)
JP (1) JP5410544B2 (es)
KR (1) KR101682889B1 (es)
CN (1) CN102239170B (es)
AR (1) AR074467A1 (es)
AU (1) AU2009322243B2 (es)
CA (1) CA2745715C (es)
CO (1) CO6390059A2 (es)
CR (1) CR20110289A (es)
DO (1) DOP2011000166A (es)
EC (1) ECSP11011109A (es)
ES (1) ES2507574T3 (es)
HN (1) HN2011001487A (es)
IL (1) IL213292A (es)
MA (1) MA32945B1 (es)
MX (1) MX2011004791A (es)
MY (1) MY150789A (es)
NZ (1) NZ593150A (es)
PA (1) PA8852301A1 (es)
PE (1) PE20110773A1 (es)
RU (1) RU2519778C2 (es)
TN (1) TN2011000223A1 (es)
TW (1) TWI441826B (es)
UA (1) UA104880C2 (es)
WO (1) WO2010065798A1 (es)
ZA (1) ZA201103261B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
AR081383A1 (es) 2010-05-11 2012-08-29 Sanofi Aventis N-heteroaril bipirrolidin carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de enfermedades del sistema nervioso central.
TW201206444A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
WO2011143148A1 (en) 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
EP2569296A1 (en) * 2010-05-11 2013-03-20 Sanofi Substituted n-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof
TW201206889A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
JP5968307B2 (ja) * 2010-05-11 2016-08-10 サノフイ 置換フェニルシクロアルキルピロリジン（ピペリジン）スピロラクタム類及びアミド類、それらの製造及び治療的使用
JP2013529198A (ja) 2010-05-11 2013-07-18 サノフイ 置換されたｎ−ヘテロシクロアルキルビピロリジニルフェニルアミド誘導体、その製造及び治療上の使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3256276A (en) * 1961-02-17 1966-06-14 Geschickter Fund Med Res Substituted spiroimides
US3258276A (en) 1964-04-06 1966-06-28 Charles E Murcott Utility chair
WO2003031432A1 (en) * 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US6889262B1 (en) 2002-06-26 2005-05-03 Advanced Micro Devices, Inc. Direct transaction mode for peripheral devices
AU2003287206A1 (en) * 2002-10-23 2004-05-13 Janssen Pharmaceutica, N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
ATE547404T1 (de) * 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
CN101263112B (zh) * 2005-07-01 2012-10-10 伊莱利利公司 组胺h3受体药物、其制备和治疗用途
NZ568292A (en) * 2005-11-10 2011-08-26 Msd Kk Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
CN101331131A (zh) 2005-12-16 2008-12-24 霍夫曼-拉罗奇有限公司 用作H3受体调节剂的吡咯并[2,3-b]吡啶衍生物
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
JP2009537596A (ja) * 2006-05-23 2009-10-29 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー ６−（４−シクロプロピルピペリジン−１−イル）−２’−メチル−［３，４’］−ビピリジン及びその医薬としての使用
US7479493B2 (en) 2006-06-29 2009-01-20 Janssen Pharmaceutica N.V. Substituted benzyl amine compounds
WO2009039431A2 (en) 2007-09-21 2009-03-26 Neurogen Corporation Substituted aryl-fused spirocyclic amines
PT2205558E (pt) 2007-10-17 2012-11-02 Sanofi Sa Amidas de n-fenil-pirrolidinilmetilpirrolidina substituídas e sua utilização terapêutica como moduladores do receptor h3 da histamina
RU2477719C2 (ru) 2007-10-17 2013-03-20 Санофи-Авентис Замещенные n-фенилбипирролидинкарбоксамиды и их терапевтическое применение
MX2010003949A (es) * 2007-10-17 2010-04-30 Sanofi Aventis N-fenil-bipirrolidina carboxamidas sustituidas y uso terapeutico de las mismas.
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.

Also Published As

Publication number Publication date
EP2373659B1 (en) 2014-07-30
IL213292A (en) 2014-01-30
NZ593150A (en) 2012-10-26
US20120238757A1 (en) 2012-09-20
DOP2011000166A (es) 2011-10-31
AU2009322243B2 (en) 2015-07-16
CN102239170B (zh) 2014-08-20
WO2010065798A1 (en) 2010-06-10
MY150789A (en) 2014-02-28
JP5410544B2 (ja) 2014-02-05
RU2011127382A (ru) 2013-01-10
HN2011001487A (es) 2013-12-02
US8383814B2 (en) 2013-02-26
CN102239170A (zh) 2011-11-09
ZA201103261B (en) 2012-01-25
AR074467A1 (es) 2011-01-19
MX2011004791A (es) 2011-05-30
US8217052B2 (en) 2012-07-10
CO6390059A2 (es) 2012-02-29
PA8852301A1 (es) 2010-07-27
TN2011000223A1 (en) 2012-12-17
KR20110095911A (ko) 2011-08-25
ES2507574T3 (es) 2014-10-15
ECSP11011109A (es) 2011-11-30
EP2373659A1 (en) 2011-10-12
US20110251225A1 (en) 2011-10-13
CA2745715A1 (en) 2010-06-10
MA32945B1 (fr) 2012-01-02
TW201033219A (en) 2010-09-16
KR101682889B1 (ko) 2016-12-06
UA104880C2 (uk) 2014-03-25
CA2745715C (en) 2014-01-28
CR20110289A (es) 2011-09-21
TWI441826B (zh) 2014-06-21
JP2012511011A (ja) 2012-05-17
IL213292A0 (en) 2011-07-31
AU2009322243A1 (en) 2011-06-23
RU2519778C2 (ru) 2014-06-20

Similar Documents

Publication Publication Date Title
PE20110773A1 (es) Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, y su preparacion
PE20090248A1 (es) Moduladores de beta-amiloide
GB0517191D0 (en) Compounds
PE20091324A1 (es) Compuestos espiro como antagonistas del receptor npy y5
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
ECSP10010599A (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
PE20071152A1 (es) Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteína quinasa activados por amp (ampk)
PE20110568A1 (es) Agentes terapeuticos 414
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
MX348920B (es) Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
TW201144306A (en) Bicyclic heteroaryl analogues as GPR119 modulators
BRPI0911035A2 (pt) ativadores de pirrolidinona glicoquinase
EA201171197A8 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
PE20110409A1 (es) Compuestos heterociclicos antiviricos
PE20121640A1 (es) Derivados de pirazina como inhibidores de bace
PE20110136A1 (es) Compuestos organicos
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20120261A1 (es) Piperidina espiro pirrolidinona y piperidinonas sustitudos como moduladores de los receptores h3
MX348606B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2).
GT200600011A (es) Procedimientos para preparar eteres de pirazolo [3,4-d] pirimidina
TN2011000368A1 (en) Fused ring compound and use thereof

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed